July 23, 2024
YH001 PLUS ENVAFOLIMAB WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SARCOMA
This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients with advanced or metastatic sarcoma, followed by Phase 2 cohorts of patients with select histologies of advanced or metastatic sarcoma.
ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT05448820?term=envafolimab&draw=3
Sponsor website: www.traconpharma.com